Q BioMed Inc. (QBIO) financial statements (2022 and earlier)
Company profile
| Business Address |
366 MADISON AVE. NEW YORK, NY 10017 |
| State of Incorp. | NV |
| Fiscal Year End | November 30 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 11/30/2021 | 11/30/2020 | 11/30/2019 | 11/30/2018 | 11/30/2017 | 11/30/2016 | 11/30/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 344 | 177 | 173 | 2,684 | 825 | 2,395 | 131 | ||
| Cash and cash equivalents | 344 | 177 | 173 | 2,684 | 825 | 1,469 | 131 | ||
| Other undisclosed cash, cash equivalents, and short-term investments | 926 | ||||||||
| Receivables | 80 | ||||||||
| Prepaid expense | 13 | 3 | |||||||
| Other undisclosed current assets | 35 | 46 | 18 | (926) | |||||
| Total current assets: | 459 | 223 | 190 | 2,697 | 827 | 1,469 | 131 | ||
| Noncurrent Assets | |||||||||
| Intangible assets, net (including goodwill) | 350 | 400 | 450 | 500 | 293 | 293 | 231 | ||
| Intangible assets, net (excluding goodwill) | 350 | 400 | 450 | 500 | 293 | 293 | 231 | ||
| Other undisclosed noncurrent assets | (293) | (293) | (231) | ||||||
| Total noncurrent assets: | 350 | 400 | 450 | 500 | |||||
| TOTAL ASSETS: | 809 | 623 | 640 | 3,197 | 827 | 1,469 | 131 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 2,370 | 1,603 | 1,988 | 392 | 464 | 498 | 91 | ||
| Accounts payable | 1,345 | 722 | 652 | ||||||
| Accrued liabilities | 954 | 838 | 1,146 | 168 | |||||
| Interest and dividends payable | 71 | 43 | 190 | 30 | 49 | ||||
| Other undisclosed accounts payable and accrued liabilities | 363 | 464 | 281 | 91 | |||||
| Debt | 3,053 | 92 | 3,243 | 100 | 296 | ||||
| Due to related parties | 72 | 4 | 8 | 8 | 8 | 71 | |||
| Other undisclosed current liabilities | 0 | 0 | 30 | 2,612 | |||||
| Total current liabilities: | 5,495 | 1,699 | 5,238 | 429 | 471 | 3,280 | 387 | ||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt, including: | 2,873 | 232 | |||||||
| Other undisclosed liabilities, other than long-term debt | 2,873 | 232 | |||||||
| Other undisclosed noncurrent liabilities | 447 | ||||||||
| Total noncurrent liabilities: | 447 | 2,873 | 232 | ||||||
| Total liabilities: | 5,495 | 1,699 | 5,686 | 3,303 | 471 | 3,512 | 387 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | (4,685) | (1,075) | (5,045) | (106) | 356 | (2,043) | (256) | ||
| Common stock | 29 | 24 | 20 | 14 | 12 | 9 | 9 | ||
| Additional paid in capital | 53,336 | 47,656 | 37,329 | 31,994 | 23,187 | 6,249 | 866 | ||
| Accumulated deficit | (64,127) | (55,886) | (42,394) | (32,114) | (22,843) | (8,302) | (1,130) | ||
| Other undisclosed stockholders' equity attributable to parent | 6,077 | 7,130 | |||||||
| Total stockholders' equity: | (4,685) | (1,075) | (5,045) | (106) | 356 | (2,043) | (256) | ||
| TOTAL LIABILITIES AND EQUITY: | 809 | 623 | 640 | 3,197 | 827 | 1,469 | 131 | ||
Income statement (P&L) ($ in thousands)
| 11/30/2021 | 11/30/2020 | 11/30/2019 | 11/30/2018 | 11/30/2017 | 11/30/2016 | 11/30/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 196 | 30 | ||||||
| Cost of revenue | (247) | (326) | ||||||
| Cost of goods and services sold | (324) | |||||||
| Gross profit: | (51) | (296) | ||||||
| Operating expenses | (7,337) | (12,849) | (8,020) | (9,020) | (12,372) | (6,347) | (952) | |
| Other operating expense, net (Other Expenses) | (2,170) | (825) | (134) | |||||
| Operating loss: | (7,389) | (13,145) | (8,020) | (18,290) | (29,083) | (14,343) | (1,087) | |
| Nonoperating expense (Other Nonoperating expense) | (2,260) | |||||||
| Interest and debt expense | (41) | (31) | (1,460) | (526) | 76 | (481) | (21) | |
| Other undisclosed income from continuing operations before equity method investments, income taxes | 31 | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (7,429) | (13,145) | (11,740) | (18,816) | (29,007) | (14,824) | (1,108) | |
| Other undisclosed income from continuing operations before income taxes | 41 | |||||||
| Loss before gain (loss) on sale of properties: | (7,389) | (13,145) | (11,740) | (18,816) | (29,007) | (14,824) | (1,108) | |
| Other undisclosed net income | 1,460 | 19,807 | 14,465 | 15,924 | 21 | |||
| Net income (loss): | (7,389) | (13,145) | (10,280) | 990 | (14,542) | 1,100 | (1,087) | |
| Other undisclosed net loss attributable to parent | (852) | (347) | (10,261) | (8,272) | ||||
| Net loss attributable to parent: | (8,241) | (13,492) | (10,280) | (9,271) | (14,542) | (7,172) | (1,087) | |
| Preferred stock dividends and other adjustments | (501) | (858) | ||||||
| Other undisclosed net income available to common stockholders, basic | 23,771 | 29,042 | 14,372 | |||||
| Net income (loss) available to common stockholders, diluted: | (8,741) | (14,350) | (10,280) | 14,500 | 14,500 | 7,200 | (1,087) | |
Comprehensive Income ($ in thousands)
| 11/30/2021 | 11/30/2020 | 11/30/2019 | 11/30/2018 | 11/30/2017 | 11/30/2016 | 11/30/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (7,389) | (13,145) | (10,280) | 990 | (14,542) | 1,100 | (1,087) | |
| Comprehensive income (loss), net of tax, attributable to parent: | (7,389) | (13,145) | (10,280) | 990 | (14,542) | 1,100 | (1,087) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.